Exane Derivatives’s Arena Pharmaceuticals Inc ARNA Stock Holding History

Exane Derivatives’s Portfolio ARNA Stock Details ARNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-356	Closed	-$33.1K	–	1102
2021 Q4	$33.1K	Sell	356 -2,072	-85%	-$137K	0.01%	547
2021 Q3	$145K	Buy	2,428 +1,052	+76%	+$62.1K	0.03%	469
2021 Q2	$91.9K	Buy	+1,376	New	+$89.7K	0.02%	552
2021 Q1	–	Sell	-448	Closed	-$34.4K	–	978
2020 Q4	$34.4K	Sell	448 -87	-16%	-$6.52K	0.01%	485
2020 Q3	$40K	Hold	535	–	–	0.01%	386
2020 Q2	$33.7K	Hold	535	–	–	0.01%	378
2020 Q1	$22.5K	Sell	535 -400	-43%	-$18.3K	0.01%	404
2019 Q4	$42.2K	Sell	935 -3,741	-80%	-$177K	0.01%	363
2019 Q3	$214K	Sell	4,676 -703	-13%	-$39.5K	0.04%	247
2019 Q2	$315K	Buy	+5,379	New	+$278K	0.06%	211

Exane Derivatives's ARNA Position: Q1 2022 in Review

Exane Derivatives sold out of Arena Pharmaceuticals Inc (ARNA) in Q1 2022, closing a stake of 356 shares — an estimated $33.1K sold.

Exane Derivatives first reported a position in ARNA in Q2 2019 and held it in 10 quarters. The position peaked at $315K in Q2 2019. 1 fund tracked by Wall St. Rank holds ARNA as of Q1 2022.

Exane Derivatives reported no remaining Arena Pharmaceuticals Inc position as of Q1 2022 after selling out during the quarter.
Exane Derivatives sold 356 Arena Pharmaceuticals Inc shares in Q1 2022, an estimated $33.1K.
Exane Derivatives first reported a position in Arena Pharmaceuticals Inc in Q2 2019 and held it in 10 quarters.
Exane Derivatives's Arena Pharmaceuticals Inc position peaked at $315K in Q2 2019.
1 fund tracked by Wall St. Rank held Arena Pharmaceuticals Inc as of Q1 2022.

Based on Exane Derivatives's 13F filing for Q1 2022, filed 22 Apr 2022.